The PROBLEM With Psilocybin - How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)

In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.

I had a blast in this interview, and I know you will find it fascinating! Enjoy!

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).

#BrightMinds #PsychedelicStocks #Psilocybin

Psychedelic Spotlight

Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

January 10, 2021June 2, 2024 Listen, Videos

In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.

To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:

What problem is Compass Pathways trying to solve?
CMPS’ clinical trial, treating depression with psilocybin
The founders and leaders of Compass Pathways
Compass’ Financials
Is CMPS stock a good investment for a retail investor?

As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Resources:
https://compasspathways.com/

https://www.webmd.com/depression/understanding-depression-basics#1

https://www.psychiatry.org/patients-families/depression/what-is-depression

https://www.nimh.nih.gov/health/statistics/major-depression.shtml

https://www.webmd.com/depression/guide/depression-treatment-options#1

https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective

https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1

https://www.beckleyfoundation.org/psilocybin-for-depression-2

https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav

https://psychedelicreview.com/person/ekaterina-malievskaia/

https://compasspathways.com/team-member/george-goldsmith/
https://compasspathways.com/team-member/lars-christian-wilde/

https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T

https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html

https://www.treehugger.com/facts-about-magic-mushrooms-4868810
https://psychedelicreview.com/person/ekaterina-malievskaia/

#CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor

Consolidating Plant Medicine, Permaculture and Indigenous Wisdom With Colette Condorcita, Decriminalize Philadelphia

June 8, 2022June 2, 2024 Listen, Podcasts

In this episode, Colette describes her diverse background working closely with plant medicines and Indigenous groups in South America, how psychedelics are intrinsically aligned with permaculture and the cultivation of sacred plants, and much more.

MindMed gets FANTASTIC News from the FDA, Causing its Stock to Skyrocket (MNMD/MMED) | Project Lucy

January 26, 2022June 2, 2024 Listen, Videos

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

MindMed (Nasdaq: MNMD, NEO: MMED) today announced that their Flagship Program, Project Lucy, has been given the green light from the FDA. MindMed is set to start a phase 2b Clinical Trial treating Generalized Anxiety Disorder with MM-102.
In response, MindMed’s stock has SKYROCKETED! It is up 39% at the time of writing and it could go higher. The psychedelic stock has been battered over the last 8 months, so it is good to see positive news affecting the price.
MindMed is a company attempting to treat mental health conditions such as Anxiety and Depression with Psychedelic Therapies.
Can psychedelics relieve anxiety and treat mental health? MindMed wants to know!

#MNMDstock# MindMed #Psychedelics

Suing the City of Oakland for Mushroom Raid with Dave Hodges

February 9, 2023June 2, 2024 Listen, Podcasts

In this episode, Dave speaks to Dennis Walker about how Oakland PD raided his church and confiscated $200,000 worth of sacraments.

Kevin Colley on Career Ending Injury and His Path to Recovery Through Psychedelic-Therapy

October 5, 2023June 2, 2024 Listen, Podcasts

Kevin Colley, a former professional hockey player with over a decade of experience, including a stint with the NHL’s New York Islanders, embarked on a profound journey earlier this year. Invited by fellow retired NHL player Riley Cote, Kevin participated in a transformative psychedelic-focused retreat as a patient of WAKE’s clinical program in Jamaica.

How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)

January 28, 2021June 2, 2024 Listen, Videos

Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.

We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests

MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)

MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf